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Background: Dyslipidemia and type 2 diabetes are two of the most significant risk factors for the 
development of cardiovascular disease. Measurement of lipoprotein subclasses provides impor-
tant information about derangements in lipid metabolism and helps refine cardiovascular risk 
assessment. Exenatide, a glucagon-like peptide 1 receptor agonist, improved glycemic  control, 
obesity, hypertension, and dyslipidemia in patients with type 2 diabetes in clinical trials.
Methods: In the DURATION-1 trial, patients with type 2 diabetes were treated with exenatide 
once weekly or twice daily for 30 weeks. This post hoc analysis evaluated the impact of 
exenatide on lipoprotein subclasses in 211 DURATION-1 patients using vertical auto profile 
methodology and the Statistical Package for the Social Sciences general linear model adjusted 
for glycosylated hemoglobin (HbA
1c
) and weight.
Results: Baseline lipids and high sensitivity C-reactive protein were normal overall based on the 
standard lipid panel. Once-weekly exenatide reduced apolipoprotein B and the apolipoprotein B 
to apolipoprotein A1 ratio (P , 0.05), independent of glycemic improvement and weight loss. 
A significant shift in lipoprotein pattern away from small, dense low-density lipoprotein-4 
 cholesterol was also observed (P , 0.05). Exenatide once weekly increased high-density 
lipoprotein-2 cholesterol, even after adjustment for changes in HbA
1c
 and weight (P , 0.05). 
Triglycerides, very low-density lipoprotein cholesterol, and high sensitivity C-reactive protein 
were reduced with both the once-weekly and twice-daily exenatide regimens (P , 0.05).
Conclusion: In this post hoc analysis, exenatide significantly improved a number of cardiovas-
cular risk markers. Continuous exenatide exposure with exenatide once weekly elicited a greater 
response than did immediate-release exenatide twice daily, generally independent of glycemic 
improvement and weight loss. Thus, in addition to improving glycemic control, exenatide induced 
favorable changes in lipid and lipoprotein metabolism and decreased systemic inflammation.
Keywords: glucagon-like protein-1 receptor agonist, incretin mimetic, dyslipidemia, type 2 
diabetes mellitus
Introduction
Dyslipidemia in patients with type 2 diabetes increases the risk of cardiovascular 
disease.1–3 In insulin-resistant states, such as type 2 diabetes, there is greater constitutive 
mobilization of fatty acids from triglyceride stores in visceral adipose tissue, increased 
hepatic secretion of very low-density lipoprotein (VLDL) cholesterol, inhibition of 
lipoprotein lipase to some degree, and activation of cholesteryl ester transfer protein. 
Given these metabolic disturbances, the typical lipid profile in patients with type 2 
diabetes includes elevated triglycerides and VLDL cholesterol, increased numbers of 
small, dense low-density lipoprotein (LDL) cholesterol and other atherogenic lipo-
proteins, and reduced high-density lipoprotein (HDL) cholesterol.2
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Reducing LDL cholesterol is the primary target of dys-
lipidemia therapy in both primary and secondary  prevention. 
However, LDL cholesterol incompletely assesses the con-
tribution of all atherogenic lipoproteins, such as VLDL or 
intermediate-density lipoprotein (IDL), to cardiovascular 
disease risk. Direct measurement of circulating apolipopro-
tein B concentrations has been proposed as a better method 
for assessing this risk because it more accurately reflects the 
true burden of all atherogenic lipoproteins.4
Restoration of glycemic control and relieving insulin 
resistance promotes reductions in serum triglyceride levels, 
primarily by reducing free fatty acid and glucose levels, 
both of which fuel hepatic triglyceride production. However, 
lowering of glucose rarely results in pronounced improve-
ments in LDL and HDL cholesterol or their subclasses. 
Given the increased burden of cardiovascular risk factors in 
patients with type 2 diabetes, it is critical to understand how 
current antihyperglycemic agents impact these risk factors 
and the progression of atherosclerosis, and to incorporate 
this knowledge into routine clinical practice. For example, 
the InterHeart study reported that smoking, dyslipidemia, 
hypertension, abdominal obesity, and diabetes account for 
80% of the risk for an acute myocardial infarction,5 and that 
the strongest risk predictor is the ratio of apolipoprotein B to 
apolipoprotein A1. Also, the Quebec Cardiovascular Study 
found that the combination of diabetes, elevated small, 
dense LDL cholesterol, and elevated apolipoprotein B 
synergistically confer a 20-fold increased risk for cardiovas-
cular events.6 Other studies suggested that high sensitivity 
C-reactive protein, a proinflammatory biomarker, helped to 
refine risk estimates beyond the measurement of established 
Framingham risk factors.7 Nissen et al8 demonstrated that 
progression of atherosclerosis is slower when atherogenic 
lipoprotein and high sensitivity C-reactive protein levels 
are both reduced.
Exenatide is a glucagon-like protein-1 receptor agonist 
that has been demonstrated to have multiple glucoregulatory 
effects in patients with type 2 diabetes, including glucose-
dependent enhancement of insulin secretion, suppression of 
inappropriately high glucagon secretion, slowing of gastric 
emptying, and reduction of food intake, usually accom-
panied by weight loss.9 Additional effects of exenatide 
are under investigation, including improved endothelial 
function, reduced systolic blood pressure, decreased oxi-
dative stress and inflammation, and improved myocardial 
bioenergetics.10–13 Preliminary investigation with nuclear 
magnetic resonance imaging demonstrated an exenatide-
induced shift away from small LDL lipoproteins towards 
larger, more buoyant LDL lipoproteins (small LDL choles-
terol change from baseline −146 ± 67 nmol/L, P = 0.037; 
large LDL cholesterol change from baseline 68 ± 27 nmol/L, 
P = 0.017) after 52 weeks of exenatide twice daily, compared 
with biphasic insulin aspart, on a background of metformin 
and sulfonylurea in patients with type 2 diabetes.14,15
In this post hoc analysis of data from the 30-week 
 DURATION-1 (Diabetes Therapy Utilization: Researching 
Changes in A
1c
, Weight and Other Factors Through Interven-
tion with Exenatide Once Weekly) clinical trial,16 the effects 
of two exenatide formulations (immediate-release exenatide 
twice daily and extended-release exenatide once weekly) 
on lipoproteins and high sensitivity C-reactive protein were 
explored using a validated vertical auto profile ultracentrifuge 
methodology.17 This is the first comprehensive lipoprotein 
subclass analysis performed for a glucagon-like protein-1 
receptor agonist in human patients with type 2 diabetes.
Materials and methods
Details on the DURATION-1 study (clinicaltrials.gov 
NCT00308139) have been reported previously.16 In brief, 
patients with type 2 diabetes were treated with exenatide 2 mg 
once weekly or exenatide 10 µg twice daily for 30 weeks. Of 
the 295 intent-to-treat patients in DURATION-1, 211 were 
assessed for lipid subclass concentrations at baseline and 
week 30 using vertical auto profile technology,17 and con-
stitute the analysis cohort. The vertical auto profile method 
involves independent measurements of total cholesterol, 
HDL cholesterol, and triglycerides.17 The validated vertical 
auto profile technique is an inverted rate zonal, single verti-
cal spin, density gradient ultracentrifugation technique that 
simultaneously and directly measures cholesterol concentra-
tions of all five lipoprotein classes (HDL cholesterol, LDL 
cholesterol-real [LDL cholesterol without lipoprotein(a) 
and IDL cholesterol], VLDL cholesterol, IDL cholesterol, 
lipoprotein(a)) and their subclasses.17,18 The vertical auto 
profile separates all lipoproteins in three steps: a two-layer 
density gradient is prepared with the bottom layer containing 
a 1:40 serum dilution with KBr; the gradient is centrifuged at 
65,000 rpm for approximately 45–60 minutes; and the layers 
are analyzed using a continuous flow cholesterol analyzer. 
Output has been validated against standardized reference tests 
from the Core Laboratory for Clinical Studies at Washington 
University School of Medicine in St Louis, MO, using beta 
quantification.19 High sensitivity C-reactive protein was mea-
sured using the Multigent CRP Vario™ assay (Ilex Medical 
Systems, Petach-Tikva, Israel) and the Architect c8000® 
system for quantitative immunoturbidometric  determination 
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(Abbott Diagnostics, Abbott Park, IL). Data were  analyzed 
using the Statistical Package for Social Sciences version 17.0 
(IBM, Armonk, NY) general linear model-univariate 
 analysis. Outcome variables of interest at study end were 
treated as dependent variables, adjusted for baseline and week 
30 change in glycosylated hemoglobin (HbA
1c
) and weight. 
The statistical significance level was set at P , 0.05.
Results
General demographics and baseline values for the total analy-
sis cohort are shown in Table 1. The patients were generally 
middle-aged, obese Caucasians with a mean HbA
1c
 of 8.2%. 
Approximately two thirds of the cohort were treated with met-
formin, and more than half with a statin. In the total analysis 
cohort, mean baseline lipid concentrations were generally 
within the normal range based on the standard lipid panel.1–3 
However, as shown below, there was actually a preponderance 
of small, dense LDL cholesterol lipoproteins, and the LDL 
cholesterol distribution in both treatment groups (exenatide 
once weekly or twice daily) was skewed towards the smaller 
LDL3 cholesterol and LDL4 cholesterol. On average, the more 
buoyant HDL2 cholesterol was below the recommended target 
goal1–3 at baseline, with a resulting apolipoprotein B to apoli-
poprotein A1 ratio above 0.6 (60%). Exenatide treatment for 
30 weeks significantly reduced mean HbA
1c
 (exenatide once 
weekly −1.6%; exenatide twice daily −1.2%) and body weight 
from baseline (exenatide once weekly −3.9 kg; exenatide twice 
daily −3.8 kg, Figure 1A and B).
Lipoprotein and apoprotein measurements for the total 
cohort are shown in Table 2, and week 30 changes after 
adjustment for HbA
1c
 and weight changes are shown in 
Figure 1C–H. Exenatide once weekly significantly reduced 
triglycerides, apolipoprotein B, the apolipoprotein B to apoli-
poprotein A1 ratio, LDL4 cholesterol, and VLDL cholesterol 
(P , 0.05). Exenatide twice daily reduced triglycerides and 
VLDL cholesterol (P , 0.05). The changes in apolipoprotein 
A1, LDL cholesterol, LDL1 cholesterol, LDL2 cholesterol, 
LDL3 cholesterol, IDL cholesterol, VLDL3 cholesterol, 
VLDL1+2 cholesterol, non-HDL cholesterol, remnant lipo-
proteins, and lipoprotein(a) cholesterol were not significant 
with either treatment. Despite no statistically significant 
effect on total HDL cholesterol after adjustment for changes 
in HbA
1c
 and weight, exenatide once weekly significantly 
increased HDL2 cholesterol (P , 0.05), but not HDL3 
 cholesterol. In contrast, twice-daily treatment with exenatide 
resulted in no change in HDL cholesterol subclasses.
Among patients with abnormal baseline lipid values,1–3 
exenatide once weekly significantly improved  apolipoprotein B, 
the apolipoprotein B to apolipoprotein A1 ratio, LDL choles-
terol, LDL3+4 cholesterol/LDL cholesterol, LDL1+2 cho-
lesterol/LDL cholesterol, triglycerides, VLDL cholesterol, 
VLDL3 cholesterol, IDL cholesterol, non-HDL cholesterol, 
and remnant lipoproteins (P , 0.05;  Figure 2A–E). Exenatide 
twice daily improved apolipoprotein B, the apolipoprotein B 
to apolipoprotein A1 ratio, LDL cholesterol, triglycerides, 
Table 1 Demographics and baseline characteristics for the 
lipoprotein subclass analysis cohort
Total cohort
ExQW 
n = 106
ExBID 
n = 105
Age (years) 56 ± 9 55 ± 10
Female (%) 36.8 47.6
Caucasian (%)
Black/African American (%)
Hispanic (%)
Asian (%)
84.9
4.7
10.4
0
73.3
11.4
14.3
1.0
A1c (%) 8.2 ± 0.9 8.2 ± 0.9
Body weight (kg) 101 ± 18 104 ± 22
BMI (kg/m2) 34.8 ± 5.0 34.9 ± 5.3
Apolipoprotein A (g/L)
Apolipoprotein B (g/L)
1.3 ± 0.2
0.81 ± 0.21
1.3 ± 0.2
0.86 ± 0.23
Apolipoprotein B/A1 (%) 61 ± 15 65 ± 17
Triglycerides (mmol/L) 2.14 ± 1.40 2.11 ± 1.44
LDL-C (mmol/L)
 LDL1-C (mmol/L)
 LDL2-C (mmol/L)
 LDL3-C (mmol/L)
 LDL4-C (mmol/L)
2.16 ± 0.80
0.22 ± 0.17
0.17 ± 0.19
0.75 ± 0.36
0.54 ± 0.29
2.42 ± 0.94
0.27 ± 0.19
0.23 ± 0.28
0.82 ± 0.43
0.56 ± 0.29
VLDL-C (mmol/L) 0.59 ± 0.20 0.60 ± 0.21
HDL-C (mmol/L)
 HDL-2 (mmol/L)
 HDL-3 (mmol/L)
1.04 ± 0.24
0.20 ± 0.09
0.84 ± 0.16
1.06 ± 0.27
0.20 ± 0.09
0.86 ± 0.20
Diabetes medications (%)
 none
 MET alone
 SFU alone
 TZD alone
 MET + TZD
 MET + SFU
 TZD + SFU
 MET + TZD + SFU
15.2
34.9
2.8
1.9
11.3
29.2
3.8
0.9
10.4
33.3
6.7
14.3
3.8
26.7
2.9
1.9
Dyslipidemia medications (%)
 Statin
 Statin + CAI
 niacin
 Fibrate
 CAI
 Fish oil
61.3
7.5
2.8
7.5
8.5
7.5
44.8
5.7
4.8
9.5
4.8
5.7
Note: Values are mean ± SD.
Abbreviations: ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; BMI, body 
mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; CAI, 
cholesterol absorption inhibitor; MET, metformin; SD, standard deviation; SFU, 
sulfonylurea; TZD, thiazolidinedione; A1c, glycosylated hemoglobin; ExQW, exenatide 
once weekly; ExBID, exenatide twice daily.
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VLDL cholesterol, IDL cholesterol, non-HDL cholesterol, 
and remnant lipoproteins (P , 0.05). Because recom-
mended HDL cholesterol concentrations differ by gender 
(.1.0 mmol/L in men and .1.3 mmol/L in women),20 these 
variables were evaluated separately for men and women. 
Results of these analyses show that exenatide once weekly 
significantly improved HDL and HDL2 cholesterol in women, 
HDL and HDL3 cholesterol in men, and HDL2/HDL  cho-
lesterol in both men and women (P , 0.05); exenatide twice 
daily significantly improved HDL3  cholesterol in men and 
HDL cholesterol in both men and women (P , 0.05). In 
the exenatide once-weekly treatment group, the  percentage 
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Figure 1 Effects of exenatide on glycosylated hemoglobin, body weight, apolipoproteins, and lipoproteins in the total analysis cohort with an overall normal lipid profile at baseline. 
Week 30 change data are independent of glycemic improvement and weight loss. (A) Glycosylated hemoglobin. (B) Body weight. (C) Apolipoprotein B. (D) Percentage of 
apolipoprotein B/apolipoprotein A1. (E) Low-density lipoprotein cholesterol and its subclasses. (F) Triglycerides, very low-density lipoprotein cholesterol, and non-high-density 
lipoprotein cholesterol. (G) High-density lipoprotein cholesterol and its subclasses. (H) Percentage changes in high-density lipoprotein cholesterol and its subclasses. (Panels A 
and B) Least squares mean + 95% confidence intervals. *Change from baseline P , 0.0001. (Panels C–G) Adjusted mean + standard error of the mean.
Notes: *Week 30 change from baseline P , 0.05. Once weekly, n = 106, twice daily, n = 105.
Abbreviations: A1c, glycosylated hemoglobin; ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; BID, twice daily; LDL-C, low-density lipoprotein cholesterol; VLDL-C, 
very low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; QW, once weekly.
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of patients achieving lipoprotein normalization1–3 was 39% 
for LDL cholesterol, 36% for triglycerides, 50% for VLDL 
cholesterol, 42% for non-HDL cholesterol, and 20% for HDL 
cholesterol. In the exenatide twice-daily treatment group, 
the percentage of patients achieving lipoprotein normaliza-
tion1–3 was 39% for triglycerides, 55% for VLDL cholesterol, 
18% for non-HDL cholesterol, and 15% for HDL cholesterol. 
 During the 30-week assessment period, doses of lipid-lowering 
agents remained generally stable in all patients in both treat-
ment groups.
In the total cohort, both exenatide formulations reduced 
high sensitivity C-reactive protein independent of glycemic 
control and weight loss (P , 0.05; Figure 2F). Among the 
patients with abnormal high sensitivity C-reactive protein at 
baseline, high sensitivity C-reactive protein was significantly 
reduced by 24% (P = 0.018). The percentages achieving high 
sensitivity C-reactive protein normalization (,3 mg/L) were 
33% with exenatide once weekly and 38% with exenatide 
twice daily.
Discussion
Evidence garnered over the past two decades has revealed the 
failure of standard lipoprotein measurements (eg, triglycerides, 
total cholesterol, LDL cholesterol, and HDL cholesterol) to 
identify many of the lipoprotein abnormalities contributing to 
cardiovascular events.21 A recent meta-analysis of LDL choles-
terol, non-HDL cholesterol, and apolipoprotein B as markers 
of cardiovascular disease demonstrated that apolipoprotein B 
was the most reliable predictor of fatal or nonfatal ischemic 
events.22 Across all studies analyzed, the mean apolipoprotein B 
relative risk ratio was 12.0% greater than for LDL cholesterol 
(P , 0.0001) and 5.7% higher than for non-HDL choles-
terol (P , 0.001). These head-to-head analyses also rank-
ordered the three markers as apolipoprotein B . non-HDL 
cholesterol . LDL cholesterol. Over a 10-year period, an 
apolipoprotein B strategy would prevent 500,000 more car-
diovascular events than a non-HDL cholesterol strategy, and 
a non-HDL cholesterol strategy would prevent 300,000 more 
cardiovascular events than an LDL cholesterol strategy.22
Comprehensive lipoprotein testing, such as the vertical 
auto profile, can better inform the clinician on the patient’s 
underlying lipid disorders, above and beyond the standard 
lipid panel, and can easily be incorporated into routine 
clinical management. This potential benefit was demon-
strated in a cohort of patients with type 2 diabetes from the 
DURATION-1 exenatide clinical trial,16 in which there was a 
preponderance of small, dense LDL cholesterol lipoproteins 
(see Table 1) not apparent from the standard lipid panel.1–3 In 
fact, the LDL cholesterol distribution in both treatment groups 
(exenatide once weekly, exenatide twice daily) was skewed 
towards the smaller LDL3 cholesterol and LDL4 cholesterol. 
On average, the more buoyant HDL2 cholesterol was below 
the recommended target goal1–3 at baseline, with a resulting 
apolipoprotein B to apolipoprotein A1 ratio above 0.6 (60%). 
Clearly, the most widely used clinical test failed to capture the 
level of cardiovascular risk accurately in these patients.
Despite the appearance of a benign lipid profile at 
baseline based on the standard lipid panel,1–3 a clinically 
important shift in lipoprotein pattern away from small, dense 
LDL4 cholesterol particles was observed with once-weekly 
exenatide treatment. This is consistent with the reduction in 
serum triglycerides that was also observed in patients treated 
with exenatide once weekly. As triglyceride availability 
in serum decreases, there is less cholesteryl ester transfer 
protein-dependent loading of LDL cholesterol particles 
with triglyceride. This, is turn, results in less hepatic lipase-
dependent lipolysis of LDL cholesterol particles, allowing 
for them to remain larger, more buoyant, and possibly 
Table 2 Apolipoprotein and lipoprotein change from baseline in 
patients with type treated with exenatide for 30 weeks for the 
lipoprotein subclass analysis cohort
ExQW 
(n = 106)
ExBID 
(n = 105)
ApoA1 (g/L) 0.016 (−0.011, 0.042) −0.001 (−0.028, 0.025)
ApoB (g/L) −0.036* (−0.065, −0.008) −0.013 (−0.041, 0.015)
ApoB/ApoA1 (%) −3.1 (−5.0, −1.3)* −1.0 (−2.8, 0.9)
Triglycerides  
(mmol/L)
−0.361 (−0.566, −0.155)* −0.339 (−0.546, −0.132)*
LDL-C (mmol/L) −0.073 (−0.192, 0.028) 0.009 (−0.111, 0.129)
LDL1-C (mmol/L) −0.008 (−0.035, 0.019) −0.006 (−0.034, 0.021)
LDL2-C (mmol/L) 0.024 (−0.008, 0.055) 0.012 (−0.019, 0.044)
LDL3-C (mmol/L) −0.020 (−0.080, 0.040) 0.050 (−0.011, 0.110)
LDL4-C (mmol/L) −0.052 (−0.098, −0.006)* −0.015 (−0.061, 0.031)
IDL-C (mmol/L) −0.005 (−0.025, 0.015) −0.005 (−0.025, 0.015)
VLDL-C (mmol/L) −0.327 (−0.360, −0.295)* −0.343 (−0.375, −0.310)*
VLDL3-C (mmol/L) −0.007 (−0.022, 0.008) 0.004 (−0.011, 0.019)
VLDL12-C  
(mmol/L)
−0.004 (−0.026, 0.018) −0.007 (−0.029, 0.015)
nonHDL-C  
(mmol/L)
−0.086 (−0.220, 0.049) 0.015 (−0.120, 0.151)
RLPs (mmol/L) −0.012 (−0.044 0.020) −0.001 (−0.034, 0.031)
Lp(a) (mmol/L) −0.012 (−0.040, 0.016) −0.023 (−0.051, 0.005)
HDL-C (mmol/L) 0.032 (−0.000, 0.065) 0.005 (−0.027, 0.038)
HDL2-C (mmol/L) 0.013 (0.002, 0.025)* 0.005 (−0.007, 0.017)
HDL3-C (mmol/L) 0.018 (−0.007, 0.043) −0.002 (−0.027, 0.023)
Notes: Values are adjusted mean (95% CI). *P , 0.05 versus baseline. Adjusted 
model included changes from baseline in A1c and weight as covariates.
Abbreviations: ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; LDL-C, 
low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; 
VLDL-C, very low-density lipoprotein cholesterol; A1c, glycosylated hemoglobin; 
Lp(a), lipoprotein(a); RLPs, remnant lipoproteins; ExQW, exenatide once weekly; 
ExBID, exenatide twice daily.
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Figure 2 Effects of exenatide on apolipoproteins, lipoproteins, and high sensitivity C-reactive protein in the subgroup of patients with abnormal lipid values1–3 at baseline. 
(A) Apolipoprotein A1, apolipoprotein B, and the ratio of these apolipoproteins; once weekly, n = 85, n = 9, and n = 22, respectively; twice daily, n = 78, 18, and 29, respectively. 
(B) Low-density lipoprotein cholesterol and subclass ratios; once weekly, n = 28, 28, and 28, respectively; twice daily, n = 36, 36, and 36, respectively. (C) Triglycerides, very 
low-density lipoprotein (VLDL) cholesterol, VLDL3 cholesterol, ratio of VLDL cholesterol/VLDL3 cholesterol, and intermediate-density lipoprotein cholesterol; once weekly, 
n = 55, 18, 77, 106, and 7, respectively; twice daily, n = 52, 20, 75, 104, and 6, respectively. (D) non-high-density lipoprotein cholesterol and remnant lipoproteins; once 
weekly, n = 26 and n = 13, respectively; and twice daily, n = 34 and n = 21, respectively. (E) Total high-density lipoprotein cholesterol and its subclasses stratified by gender 
and overall subclass ratio; once weekly, n = 51, 39, 57, 22, 47, and 95, respectively; twice daily, n = 46, 39, 55, 17, 44, and 96, respectively. (F) High sensitivity C-reactive 
protein in the total cohort; once weekly, n = 104; twice daily, n = 103.
Notes: High sensitivity C-reactive protein in the subgroup with baseline . 3 mg/L and ,10 mg/L; once weekly, n = 41; twice daily, n = 32. Adjusted mean + standard error 
of the mean. *Week 30 change from baseline P , 0.05.
Abbreviations: BL, baseline; ApoB, apolipoprotein B; ApoA1, apolipoprotein A1; LDL-C, low-density lipoprotein cholesterol; BID, twice daily; HDL-C, high-density 
lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; IDL-C, intermediate-density lipoprotein cholesterol; RLPs, remnant lipoproteins; hsCRP, high 
sensitivity C-reactive protein; QW, once weekly.
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less atherogenic. Exenatide once weekly also significantly 
increased the levels of more buoyant HDL2 cholesterol par-
ticles, even after adjustment for treatment effects on HbA
1c
 
and body weight. This shift suggests that HDL cholesterol 
particles in exenatide-treated patients are maturing, and may 
not be as vulnerable to lipolysis and catabolism by hepatic 
lipase. Although the subject of debate, investigations have 
suggested that the HDL2 cholesterol subtype may have a 
greater cardioprotective effect in type 2 diabetes.23 Given 
that the pathogenic potential of small dense LDL cholesterol 
and apolipoprotein B may be further amplified by insulin 
resistance and the hyperglycemia of type 2 diabetes, the 
additional 4% reduction in apolipoprotein B, 1.6% reduc-
tion in HbA
1c
, and 4 kg weight loss observed with exenatide 
therapy in this study would be expected to contribute to 
overall risk reduction. Considering the changes in serum 
levels of apolipoproteins, lipids, and lipoproteins observed in 
this cohort, at a minimum, exenatide therapy was associated 
with improvements in lipoprotein metabolism.
Hypertriglyceridemia is a marker of metabolic disease, and 
is assuming an increasingly important role in the assessment and 
management of cardiovascular disease risk.24 Prospective stud-
ies support a strong link between triglyceride concentrations 
and cardiovascular risk in patients with type 2 diabetes, and 
in individuals with lower levels of HDL and LDL cholesterol. 
The incomplete hydrolysis of triglyceride-rich chylomicrons 
and VLDL particles results in atherogenic cholesterol-enriched 
remnant lipoproteins and elevated nonfasting triglycerides 
that have been strongly correlated with high levels of remnant 
 lipoproteins. In our post hoc analysis, both exenatide formu-
lations significantly reduced circulating concentrations of 
triglycerides and VLDL cholesterol. The beneficial effects of 
exenatide on the entire spectrum of apolipoproteins, lipopro-
teins, and lipoprotein subclasses were especially apparent in 
patients with abnormal baseline values. Exenatide treatment 
improved apolipoprotein B, LDL cholesterol, and several sub-
class risk indicators, including a number of other atherogenic 
cholesterol-rich lipoproteins, triglycerides, and antiatherogenic 
HDL cholesterol, HDL2 cholesterol, and HDL3 cholesterol.
Several previous studies offer additional insights 
into the effects of exenatide on circulating lipids and 
lipoproteins.10–12,25–29 In an open-label extension of the 
first three Phase III exenatide twice daily clinical trials, 
314 patients with type 2 diabetes treated with metformin 
and/or sulfonylurea plus exenatide twice daily for 82 weeks 
had significantly reduced triglycerides (−0.43 mmol/L) and 
elevated HDL cholesterol (+0.12 mmol/L).25 There were 
trends for reductions in total cholesterol,  apolipoprotein B, 
and LDL  cholesterol. By 3.5 years of twice-daily exenatide 
treatment, the 151 evaluable patients had significant reductions 
from baseline in triglycerides (−12%), total cholesterol (−5%), 
and LDL cholesterol (−6%).26 In addition, HDL cholesterol 
was significantly increased by 24%. Although the 25% of 
patients who lost the most weight had the greatest improve-
ments in triglycerides and HDL cholesterol, there was minimal 
correlation between weight change and lipid improvements for 
the total cohort. Correlations between HbA
1c
 or fasting plasma 
glucose and serum lipid concentrations were similarly low. In a 
clinical practice setting, Bhushan et al10 reported a retrospective 
analysis of the laboratory and medical records of 176 adults 
with both type 2 diabetes and metabolic syndrome treated 
with exenatide twice daily for 16 weeks. Exenatide signifi-
cantly reduced total cholesterol and LDL cholesterol, but not 
triglycerides. Of interest, these results were not attributable to 
changes in concomitant dyslipidemia medications. In a later 
clinical trial, Bunck et al11 evaluated 69 patients with type 2 
diabetes treated chronically with metformin and exenatide 
twice daily or insulin glargine for a year. Compared with 
insulin, exenatide twice daily significantly reduced post-meal 
excursions in triglycerides, apolipoprotein B48, VLDL cho-
lesterol, and free fatty acids, and increased HDL cholesterol. 
Finally, acute exenatide administration suppressed postpran-
dial excursions of proatherogenic lipoproteins in overweight/
obese adults with impaired glucose tolerance or recent onset 
type 2 diabetes (57% treated with statins).12,27 One injec-
tion of exenatide markedly reduced postprandial elevation 
of triglycerides, apolipoprotein B-48, apolipoprotein CIII, 
remnant lipoprotein cholesterol, and remnant lipoprotein 
triglyceride (each P , 0.05 versus placebo). A subgroup 
analysis found that postprandial endothelial function was 
higher after exenatide than after placebo (P = 0.0002) and 
that exenatide-induced changes in postprandial triglyceride 
concentrations explained 64% of this effect. Further, the effects 
of exenatide on postprandial lipoproteins were not affected 
by the degree of loss of glucose control nor by dyslipidemia 
treatment with statins. In the DURATION-2 study, patients 
with type 2 diabetes suboptimally controlled with metformin 
and treated with exenatide once weekly for 26 weeks had 
significantly increased HDL cholesterol compared with 
baseline (P , 0.05),28 and this improvement was maintained 
out to 52 weeks.29 Taken together, these data lend further sup-
port to a role for exenatide in improving the typical diabetic 
proatherogenic profile that is at least partially independent of 
the effects of exenatide on glycemic control and weight loss. 
Although little is known concerning potential mechanisms to 
explain the effects of exenatide on lipoproteins, in a recent 
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study, exenatide acutely suppressed intestinal lipoprotein 
production, possibly through a direct effect on intestinal 
lipoprotein production, but  independent of changes in body 
weight, satiety, gastric emptying, glucagon, and circulating 
free fatty acid concentrations.30
The interplay between proinflammatory cytokines and 
lipid homeostasis has been well described.31 Type 2 diabetes 
is associated with a chronically heightened level of systemic 
inflammation characterized by increased plasma levels of 
numerous inflammatory biomarkers, including high sensitivity 
C-reactive protein. In a large, representative study, the relation-
ship between circulating levels of high sensitivity C-reactive 
protein and cardiovascular disease mortality was tracked over 
7 years.32 In these patients, individuals with a baseline high 
 sensitivity C-reactive protein . 3 mg/L were significantly 
more likely to die from cardiovascular disease (about 1.5-
fold) than were individuals with high sensitivity C-reactive 
protein # 3 mg/L (P , 0.004). Furthermore, this association 
remained even after adjustment for age, gender, total cholesterol, 
HDL cholesterol, triglycerides, diabetes duration, HbA
1c
, hyper-
tension, smoking, residence area, and body mass index, and was 
independent of pre-existing myocardial infarction events.
Exenatide treatment was observed to reduce high  sensitivity 
C-reactive protein significantly, independent of glycemic con-
trol and weight loss in the total lipid-analysis cohort. When 
patients with type 2 diabetes suboptimally controlled with 
metformin and/or sulfonylurea were treated with exenatide 
twice daily for 16 weeks, high sensitivity C-reactive protein 
was significantly reduced (from 0.4 ± 0.5 to 0.2 ± 0.3 mg/L) 
compared with placebo (increased from 0.6 ± 0.4 to 
1.4 ± 1.6 mg/L; P , 0.05).33 In the  DURATION-2 study, 
patients whose type 2 diabetes was suboptimally controlled 
with metformin and who were treated with exenatide once 
weekly for 26 weeks had significantly reduced high sensitiv-
ity C-reactive protein (P , 0.05),28 and this improvement 
reached −25% by week 52.29
The limitations of this study include the post hoc nature 
of the analysis, the small number of patients, especially those 
with abnormal baseline values, and the open-label treatment 
design. Furthermore, these analyses were exploratory in 
nature, and the results should be considered primarily as 
hypothesis generating.
Conclusion
This post hoc analysis demonstrated that exenatide therapy 
may improve a wide spectrum of cardiovascular disease risk 
markers. Continuous exenatide exposure with once-weekly 
administration elicited a greater response than exenatide 
twice daily. Importantly, these improvements were at least 
partially mediated through mechanisms distinct from the 
effects of exenatide on hyperglycemia and obesity. Thus, 
administration of once-weekly exenatide has the potential 
to modify cardiovascular disease risk factors beneficially 
in patients with type 2 diabetes and, thus, warrants further 
clinical investigation in prospective studies. An ongoing, pro-
spective morbidity and mortality outcomes study (EXSCEL, 
clinicaltrials.gov NCT01144338) is expected to elucidate 
further the potential cardiovascular benefits stemming from 
the effect of exenatide once weekly on dyslipidemia.
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